论文部分内容阅读
本文运用荧光偏振免疫分析法(Fluorecence Polarization Immunoassay,FPIA)测定6例中剂量氨甲喋呤(1000mg/m~2)24h静滴治疗儿童急性淋巴白血病患儿的血药浓度。用电子计算机按二室模型求得药动学参数:t(1/2)a(h)1.2317±0.5635,t(1/2)β(h)11.7687±6.663,K_(12)(h~(-1))0.2758±0.1725,K_(21)(h~(-1))0.1948±0.1716,K_(10)(h~(-1))0.3530±0.2413。维持有效抑制人体骨髓DNA生物合成的血药浓度(>0.02μmol/L)时间达144h 中剂量氨甲喋呤治疗的毒副反应主要是肝脏损害和骨髓轻度抑制,停药后恢复正常,因此在(CF)解救措施得当时,毒副反应仍属轻微,临床上是可以接受的。
Fluorescence Polarization Immunoassay (FPIA) was used to determine the plasma concentration of 6 methotrexate (1000mg / m ~ 2) for 6 h in children with acute lymphoblastic leukemia. The pharmacokinetic parameters were calculated by two-compartment model with computer: t (1/2) a (h) 1.2317 ± 0.5635, t (1/2) β (h) 11.7687 ± 6.663, K 12 -1)) 0.2758 ± 0.1725, K 21 (h -1) 0.1948 ± 0.1716, K 10 (h -1) 0.3530 ± 0.2413. Maintaining effective blood concentration (> 0.02μmol / L) of human bone marrow DNA biosynthesis up to 144h Methotrexate dose-response is mainly liver damage and mild suppression of bone marrow, returned to normal after withdrawal, so in the (CF Toxicity was still mild and clinically acceptable at the time of rescue.